SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (23298)3/24/2007 10:52:40 PM
From: Arthur Radley  Respond to of 52153
 
Thanks Harry for the input on ALXA. I guess we will get a better understanding Monday when they announce Phase II results.



To: NeuroInvestment who wrote (23298)3/26/2007 11:12:30 AM
From: Biomaven  Respond to of 52153
 
<ALXA>

Well their migraine results turned out to be decent - pretty comparable to monotherapy triptans (but worse then POZN's Trexima combo).

But if this is really intended as a rescue medication, shouldn't they be studying it in that context? If it's intended as first-line, then they face the same safety concerns on TD as POZN's earlier drug did; if it's intended as rescue then that's a much tougher enrollment/efficacy hurdle than this trial.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News